Abstract
Glucocorticoid (GC)-induced osteoporosis (GIO) is characterized by impaired bone formation, which can be alleviated by tanshinol, an aqueous polyphenol isolated from Salvia miltiorrhiza Bunge. In this study we investigated the molecular mechanisms underlying GC-induced modulation of osteogenesis as well as the possibility of using tanshinol to interfere with GIO. Female SD rats aged 4 months were orally administered distilled water (Con), prednisone (GC, 5 mg·kg−1·d−1), GC plus tanshinol (Tan, 16 mg·kg−1·d−1) or GC plus resveratrol (Res, 5 mg·kg−1·d−1) for 14 weeks. After the rats were sacrificed, samples of bone tissues were collected. The changes in bone formation were assessed using Micro-CT, histomorphometry, and biomechanical assays. Expression of Kruppel-like factor 15 (KLF15), peroxisome proliferator-activated receptor γ 2 (PPARγ 2) and other signaling proteins in skeletal tissue was measured with Western blotting and quantitative RT-PCR. GC treatment markedly increased the expression of KLF15, PPARγ2, C/EBPα and aP2, which were related to adipogenesis, upregulated FoxO3a pathway proteins (FoxO3a and Gadd45a), and suppressed the canonical Wnt signaling (β-catenin and Axin2), which was required for osteogenesis. Thus, GC significantly decreased bone mass and bone quality. Co-treatment with Tan or Res effectively counteracted GC-impaired bone formation, suppressed GC-induced adipogenesis, and restored abnormal expression of the signaling molecules in GIO rats. We conclude that tanshinol counteracts GC-decreased bone formation by inhibiting marrow adiposity via the KLF15/PPARγ2/FoxO3a/Wnt pathway.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Suzuki Y . Secondary osteoporosis. A review of recent evidence focusing on glucocorticoid-induced osteoporosis and osteoporosis associated with rheumatoid arthritis. Clin Calcium 2007; 17: 104–7.
Rizzoli R, Adachi JD, Cooper C, Dere W, Devogelaer JP, Diez-Perez A, et al. Management of glucocorticoid-induced osteoporosis. Calcified Tissue Int 2012; 91: 225–43.
Yao W, Cheng Z, Busse C, Pham A, Nakamura MC, Lane NE . Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice. Arthritis Rheum 2008; 58: 1674–86.
Gimble JM, Nuttall ME . The relationship between adipose tissue and bone metabolism. Clin Biochem 2012; 45: 874–79.
Mikami Y, Lee M, Irie S, Honda MJ . Dexamethasone modulates osteogenesis and adipogenesis with regulation of osterix expression in rat calvaria-derived cells. J Cell Physiol 2011; 226: 739–48.
Cui L, Li T, Liu Y, Zhou L, Li P, Xu B, et al. Salvianolic acid B prevents bone loss in prednisone-treated rats through stimulation of osteogenesis and bone marrow angiogenesis. PLoS One 2012; 7: e34647.
Cristancho AG, Lazar MA . Forming functional fat: a growing understanding of adipocyte differentiation. Nat Rev Mol Cell Biol 2011; 12: 722–34.
Zhuang H, Zhang X, Zhu C, Tang X, Yu F, Shang GW, et al. Molecular mechanisms of PPAR-gamma governing MSC osteogenic and adipogenic differentiation. Curr Stem Cell Res Ther 2016; 11: 255–64.
Kawai M, Rosen CJ . PPARgamma: a circadian transcription factor in adipogenesis and osteogenesis. Nat Rev Endocrinol 2010; 6: 629–36.
McConnell BB, Yang VW . Mammalian Kruppel-like factors in health and diseases. Physiol Rev 2010; 90: 1337–81.
Asada M, Rauch A, Shimizu H, Maruyama H, Miyaki S, Shibamori M, et al. DNA binding-dependent glucocorticoid receptor activity promotes adipogenesis via Kruppel-like factor 15 gene expression. Lab Invest 2011; 91: 203–15.
Ito S, Suzuki N, Kato S, Takahashi T, Takagi M . Glucocorticoids induce the differentiation of a mesenchymal progenitor cell line, ROB-C26 into adipocytes and osteoblasts, but fail to induce terminal osteoblast differentiation. Bone 2007; 40: 84–92.
Ahmed M, Gaffen SL . IL-17 inhibits adipogenesis in part via C/EBPalpha, PPARgamma and Kruppel-like factors. Cytokine 2013; 61: 898–905.
Hossain MG, Iwata T, Mizusawa N, Shima SWN, Okutsu T, Ishimoto K, et al. Compressive force inhibits adipogenesis through COX-2-mediated down-regulation of PPARγ2 and C/EBPα. J Biosci Bioeng 2010; 109: 297–303.
Graneli C, Karlsson C, Brisby H, Lindahl A, Thomsen P . The effects of PPAR-gamma inhibition on gene expression and the progression of induced osteogenic differentiation of human mesenchymal stem cells. Connect Tissue Res 2014; 55: 262–74.
Yang Y, Su Y, Wang D, Chen Y, Liu Y, Luo S, et al. Tanshinol rescues the impaired bone formation elicited by glucocorticoid involving in KLF15 pathway. Oxid Med Cell Longev 2016; 1092746: doi: 10.115/2016/1092746.
Shimizu N, Yoshikawa N, Ito N, Maruyama T, Suzuki Y, Takeda S, et al. Crosstalk between glucocorticoid receptor and nutritional sensor mTOR in skeletal muscle. Cell Metab 2011; 13: 170–82.
Yang Y, Su Y, Wang D, Chen Y, Wu T, Li G, et al. Tanshinol attenuates the deleterious effects of oxidative stress on osteoblastic differentiation via Wnt/FoxO3a signaling. Oxid Med Cell Longev 2013; 2013.
Lam FF, Yeung JH, Chan KM, Or PM . Relaxant effects of danshen aqueous extract and its constituent danshensu on rat coronary artery are mediated by inhibition of calcium channels. Vascul Pharmacol 2007; 46: 271–7.
Cui L, Liu YY, Wu T, Ai CM, Chen HQ . Osteogenic effects of D+beta-3,4-dihydroxyphenyl lactic acid (salvianic acid A, SAA) on osteoblasts and bone marrow stromal cells of intact and prednisone-treated rats. Acta Pharmacol Sin 2009; 30: 321–32.
Luo S, Yang Y, Chen J, Zhong Z, Huang H, Zhang J, et al. Tanshinol stimulates bone formation and attenuates dexamethasone-induced inhibition of osteogenesis in larval zebrafish. J Orthop Transl 2016; 4: 35–45.
Hu P, Zhao L, Chen J . Physiologically achievable doses of resveratrol enhance 3T3-L1 adipocyte differentiation. Eur J Nutr 2015; 54: 569–79.
Wang S, Liang X, Yang Q, Fu X, Rogers CJ, Zhu M, et al. Resveratrol induces brown-like adipocyte formation in white fat through activation of AMP-activated protein kinase (AMPK) [alpha]1. Int J Obes 2015; 39: 967–76.
Zannas AS, Arloth J, Carrillo-Roa T, Iurato S, Roh S, Ressler KJ, et al. Lifetime stress accelerates epigenetic aging in an urban, African American cohort: relevance of glucocorticoid signaling. Genome Biol 2015; 16: 266.
Almeida M, Han L, Ambrogini E, Weinstein RS, Manolagas SC . Glucocorticoids and tumor necrosis factor alpha increase oxidative stress and suppress Wnt protein signaling in osteoblasts. J Biol Chem 2011; 286: 44326–35.
Seibel MJ, Cooper MS, Zhou H . Glucocorticoid-induced osteoporosis: mechanisms, management, and future perspectives. Lancet Diabetes Endocrinol 2013; 1: 59–70.
Simon D, Alberti C, Alison M, Le Henaff L, Chevenne D, Boizeau P, et al. Effects of recombinant human growth hormone for 1 year on body composition and muscle strength in children on long-term steroid therapy: randomized controlled, delayed-start study. J Clin Endocrinol Metab 2013; 98: 2746–54.
Liu XY, Shi JH, Du WH, Fan YP, Hu XL, Zhang CC, et al. Glucocorticoids decrease body weight and food intake and inhibit appetite regulatory peptide expression in the hypothalamus of rats. Exp Ther Med 2011; 2: 977–84.
Lin S, Huang J, Zheng L, Liu Y, Liu G, Li N, et al. Glucocorticoid-induced osteoporosis in growing rats. Calcif Tissue Int 2014; 95: 362–73.
Shan T, Liu W, Kuang S . Fatty acid binding protein 4 expression marks a population of adipocyte progenitors in white and brown adipose tissues. FASEB J 2013; 27: 277–87.
Devlin MJ, Rosen CJ . The bone-fat interface: basic and clinical implications of marrow adiposity. Lancet Diabetes Endocrinol 2015; 3: 141–7.
Colaianni G, Brunetti G, Faienza MF, Colucci S, Grano M . Osteoporosis and obesity: role of Wnt pathway in human and murine models. World J Orthop 2014; 5: 242.
Rauch A, Seitz S, Baschant U, Schilling AF, Illing A, Stride B, et al. Glucocorticoids suppress bone formation by attenuating osteoblast differentiation via the monomeric glucocorticoid receptor. Cell Metab 2010; 11: 517–31.
Acknowledgements
The study was supported by the National Natural Science Foundation of China (No 81673814, 81273518), by the Science and Technology Planning Project of Guangdong Province (No 2016A020215148), and by the Medical Scientific Research Foundation of Guangdong Province (No A2016293).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yang, Yj., Zhu, Z., Wang, Dt. et al. Tanshinol alleviates impaired bone formation by inhibiting adipogenesis via KLF15/PPARγ2 signaling in GIO rats. Acta Pharmacol Sin 39, 633–641 (2018). https://doi.org/10.1038/aps.2017.134
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/aps.2017.134
Keywords
This article is cited by
-
Biological effect of bone marrow mesenchymal stem cell- derived extracellular vesicles on the structure of alveolar bone in rats with glucocorticoid-induced osteoporosis
BMC Musculoskeletal Disorders (2023)
-
Tanshinol Inhibits Periodontitis Through IκBα Promotion
Revista Brasileira de Farmacognosia (2023)
-
The role of Serpina3n in the reversal effect of ATRA on dexamethasone-inhibited osteogenic differentiation in mesenchymal stem cells
Stem Cell Research & Therapy (2021)
-
miR-133a silencing rescues glucocorticoid-induced bone loss by regulating the MAPK/ERK signaling pathway
Stem Cell Research & Therapy (2021)
-
Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment
Nature Reviews Endocrinology (2020)
